Short answer
Fulgent Genetics, Inc. (FLGT) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $85M (up 4.4% year over year) with net income of −$30M.
Q2 2026 key financials · XBRL
- Revenue
- $85M
- +4.4% YoY · +20.0% QoQ
- Net income
- −$30M
- −55.8% YoY · −18.9% QoQ
- Operating margin
- -42.2%
- Gross margin
- 30.1%
Source: XBRL data from the Fulgent Genetics, Inc. (FLGT) Q2 2026 10-Q on SEC EDGAR. USD.
Fulgent Genetics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $85.4M, up 4% YoY from $81.8M, driven by anatomic pathology growth
- Anatomic pathology $37.5M, up 33%; precision diagnostics $41.5M, down 13%
- Gross margin 30% vs 42% YoY; operating loss $36.1M vs $19.7M
- Cash, restricted cash, and marketable securities $551.5M vs $705.5M at December 31, 2025
- Bako Acquisition funded from existing cash; largest customer revenue expected to continue declining in 2026
Risk Factors
- No material risk-factor changes from the 2025 Annual Report
- Regulatory and compliance risks carried forward without quarterly updates
- Competitive and operational risks remain those identified in the 2025 Annual Report
- Stock-repurchase liquidity allocation: $75.8 million remained available at June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulgent Genetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.